NEWTON, Mass.--(BUSINESS WIRE)--Novelos Therapeutics, Inc. (OTCBB: NVLT), a biotechnology company focused on the development of therapeutics to treat cancer and hepatitis, today announced that Harry Palmin, President and CEO of Novelos, purchased 100,000 shares of the company stock this week in market transactions, after the filing of the 10-QSB for September 30, 2006 period on November 6, 2006.
